Nephrotic Syndrome With Cancer Immunotherapies: A Report of 2 Cases

      Oncologic immunotherapies use a patient's immune response to eliminate tumor cells by modulation of immune checkpoints, including programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) proteins. Immune-mediated sequelae, including interstitial nephritis, have been reported; however, glomerular disease appears rare. We describe 2 cases of nephrotic syndrome in patients treated with these agents. Patient 1 received the anti–PD-1 antibody pembrolizumab for Hodgkin lymphoma. Following his second dose, he developed nephrotic syndrome and acute kidney injury. Biopsy showed diffuse foot-process effacement consistent with minimal change disease and findings of acute tubular injury. Pembrolizumab therapy cessation and corticosteroid treatment yielded improvement in proteinuria and acute kidney injury. Patient 2 received the CTLA-4 antibody ipilimumab for melanoma. He developed nephrotic syndrome with biopsy changes consistent with minimal change disease. Ipilimumab therapy was stopped and proteinuria resolved following corticosteroid treatment. Ipilimumab rechallenge caused relapse of nephrotic-range proteinuria. These cases suggest an association between therapeutic immune activation and the development of nephrotic syndrome. Given the increasing prevalence of oncologic immunotherapies, monitoring patients for renal sequelae is warranted.

      Index Words

      To read this article in full you will need to make a payment


      Subscribe to American Journal of Kidney Diseases
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Garon E.B.
        • Rizvi N.A.
        • Hui R.
        • et al.
        Pembrolizumab for the treatment of non-small-cell lung cancer.
        N Engl J Med. 2015; 372: 2018-2028
        • Hodi F.S.
        • O'Day S.J.
        • McDermott D.F.
        • et al.
        Improved survival with ipilimumab in patients with metastatic melanoma.
        N Engl J Med. 2010; 363: 711-723
        • Perazella M.A.
        • Izzedine H.
        New drug toxicities in the onco-nephrology world.
        Kidney Int. 2015; 87: 909-917
        • Fadel F.
        • El Karoui K.
        • Knebelmann B.
        Anti-CTLA4 antibody-induced lupus nephritis.
        N Engl J Med. 2009; 361: 211-212
        • Thajudeen B.
        • Madhrira M.
        • Bracamonte E.
        • Cranmer L.D.
        Ipilimumab granulomatous interstitial nephritis.
        Am J Ther. 2015; 22: e84-e87
        • Cortazar F.B.
        • Marrone K.A.
        • Troxell M.L.
        • et al.
        Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors.
        Kidney Int. 2016; 90: 638-647
        • Shirali A.C.
        • Perazella M.A.
        • Gettinger S.
        Association of acute interstitial nephritis with programmed cell death 1 inhibitor therapy in lung cancer patients.
        Am J Kidney Dis. 2016; 68: 287-291
        • Alpers C.E.
        • Cotran R.S.
        Neoplasia and glomerular injury.
        Kidney Int. 1986; 30: 465-473
        • Dabbs D.J.
        • Striker L.M.
        • Mignon F.
        • Striker G.
        Glomerular lesions in lymphomas and leukemias.
        Am J Med. 1986; 80: 63-70
        • Glassock R.J.
        Secondary minimal change disease.
        Nephrol Dial Transplant. 2003; 18: vi52-vi58
        • Auguet T.
        • Lorenzo A.
        • Colomer E.
        • et al.
        Recovery of minimal change nephrotic syndrome and acute renal failure in a patient with renal cell carcinoma.
        Am J Nephrol. 1998; 18: 433-435
        • Martinez-Vea A.
        • Panisello J.M.
        • Garcia C.
        • et al.
        Minimal-change glomerulopathy and carcinoma. Report of two cases and review of the literature.
        Am J Nephrol. 1993; 13: 69-72
        • Audard V.
        • Larousserie F.
        • Grimbert P.
        • et al.
        Minimal change nephrotic syndrome and classical Hodgkin's lymphoma: report of 21 cases and review of the literature.
        Kidney Int. 2006; 69: 2251-2260
        • Kidd J.M.
        • Gizaw A.B.
        Ipilimumab-associated minimal-change disease.
        Kidney Int. 2016; 89: 720
        • Lagrue G.
        • Xheneumont S.
        • Branellec A.
        • Hirbec G.
        • Weil B.
        A vascular permeability factor elaborated from lymphocytes. I. Demonstration in patients with nephrotic syndrome.
        Biomedicine. 1975; 23: 37-40
        • McCarthy E.T.
        • Sharma M.
        • Savin V.J.
        Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis.
        Clin J Am Soc Nephrol. 2010; 5: 2115-2121
        • Matsumoto K.
        • Kanmatsuse K.
        Interleukin-18 and interleukin-12 synergize to stimulate the production of vascular permeability factor by T lymphocytes in normal subjects and in patients with minimal-change nephrotic syndrome.
        Nephron. 2000; 85: 127-133
        • Matsumoto K.
        • Kanmatsuse K.
        Transforming growth factor-beta1 inhibits vascular permeability factor release by T cells in normal subjects and in patients with minimal-change nephrotic syndrome.
        Nephron. 2001; 87: 111-117
        • Reiser J.
        • von Gersdorff G.
        • Loos M.
        • et al.
        Induction of B7-1 in podocytes is associated with nephrotic syndrome.
        J Clin Invest. 2004; 113: 1390-1397
        • Butte M.J.
        • Keir M.E.
        • Phamduy T.B.
        • Sharpe A.H.
        • Freeman G.J.
        Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses.
        Immunity. 2007; 27: 111-122
        • Yu C.C.
        • Fornoni A.
        • Weins A.
        • et al.
        Abatacept in B7-1-positive proteinuric kidney disease.
        N Engl J Med. 2013; 369: 2416-2423
        • Gagliardini E.
        • Novelli R.
        • Corna D.
        • et al.
        B7-1 is not induced in podocytes of human and experimental diabetic nephropathy.
        J Am Soc Nephrol. 2016; 27: 999-1005
        • Larsen C.P.
        • Messias N.C.
        • Walker P.D.
        B7-1 immunostaining in proteinuric kidney disease.
        Am J Kidney Dis. 2014; 64: 1001-1003